By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678

Key Statistics

Ownership: Public

Web Site: OncoGenex Pharmaceuticals Inc.
Symbol: OGXI

Company News
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2014 8/8/2014 7:48:52 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2014 8/7/2014 2:16:41 PM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer 8/7/2014 8:23:16 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Second Quarter 2014 On August 7, 2014 7/24/2014 10:23:03 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment 7/1/2014 8:20:38 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Pricing Of $24 Million Underwritten Registered Direct Offering 6/27/2014 8:37:50 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Retrenches, And Searches For Answers, After Failed Trial 5/22/2014 7:45:55 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For First Quarter 2014 5/1/2014 7:33:54 AM
OncoGenex Pharmaceuticals Inc. (OGXI)'s Long Awaited Cancer Drug Ends With A Phase 3 Stumble; Stock Down -60.31% At Market Close (April 28, 2014) 4/28/2014 6:47:33 AM
OncoGenex Pharmaceuticals Inc. Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer 4/23/2014 9:00:13 AM